BFRA - Biofrontera: Why This Small German Company Can Become The Next Hot Stock
Biofrontera (BFRA; BFFTF) has been gradually shifting from a biotech company into a focused pharmaceutical company with specialization in dermatology. The central turning point was the European approval of the self-developed medication Ameluz for the photodynamic therapy of actinic keratosis in 2011. Since then, Biofrontera has made further important progress, such as acquiring the FDA approval of Ameluz in the USA. Please visit our articles Biofrontera: Potential Market Opportunities After FDA And EMA Approval and Biofrontera: Ameluz - The Key Future Value Driver to gain more insight about the company. Recently, Biofrontera